News Hub

Real-time financial, economic, and global news with market-focused context and analysis.

Coverage spans equities, macroeconomic data, commodities, currencies, technology, politics, and global events—paired with analysis that highlights why each development matters for traders and investors. From breaking headlines to hourly market snapshots and in-depth articles, the News Hub is designed to help you stay informed, oriented, and ahead of market-moving events.

  • No major market-moving headlines were released in the past hour.
  • No scheduled economic data or central-bank announcements occurred during the past hour.
  • No significant corporate earnings, M&A filings, or IPOs were reported in the past hour.
  • No new geopolitical incidents or government policy shifts were reported in the past hour.
  • No material regulatory actions or legal rulings affecting markets were announced in the past hour.
  • News flow was light, leaving markets without fresh catalysts in the past hour.

Latest Articles

Star Equity Holdings to Present at Upcoming Conferences

Star Equity Holdings to Present at Upcoming Conferences

Star Equity Holdings, Inc., a diversified holding company, announced that its management team will present and host virtual investor meetings at the Sidoti Small Cap Conference and Noble Capital Markets’ Emerging Growth Virtual Equity Conference in late September and early October 2026. The company operates in four core segments: Building Solutions…

Phase 3 Pediatric EMPAVELI Data Published in Clinical Journal of the American Society of Nephrology Show Reduction in Proteinuria and Stabilized Kidney Function in Adolescents with C3G or Primary IC-MPGN

Phase 3 Pediatric EMPAVELI Data Published in Clinical Journal of the American Society of Nephrology Show Reduction in Proteinuria and Stabilized Kidney Function in Adolescents with C3G or Primary IC-MPGN

Biogen Inc. announced the publication of Phase 3 VALIANT study data showing that EMPAVELI significantly reduces proteinuria and stabilizes kidney function in adolescents aged 12-17 with C3 glomerulopathy (C3G) and primary immune complex membranoproliferative glomerulonephritis (IC-MPGN). The study results support the recent FDA label expansion to i…

Steve Mayer Joins TFI International Board of Directors

Steve Mayer Joins TFI International Board of Directors

TFI International Inc., a leading North American transportation and logistics company, announces the appointment of Steve Mayer to its Board of Directors effective October 29, 2026. Mayer brings over 30 years of investment banking experience, with a focus on cross-border M&A and capital markets, particularly between Canada and the U.S. His addition…

BRT Apartments Corp. Declares Third Quarter Quarterly Dividend and Announces Replenishment of Current Stock Repurchase Program

BRT Apartments Corp. Declares Third Quarter Quarterly Dividend and Announces Replenishment of Current Stock Repurchase Program

BRT Apartments Corp., a real estate investment trust specializing in multifamily properties, announced a quarterly dividend of $0.25 per share payable in October 2026 and has replenished its share repurchase program, increasing the authorized buyback amount to $10 million. The company owns or has interests in 31 multifamily properties with 8,311 un…

Coherent Expands Pluggable Optical Line Systems Portfolio with Full C-Band Amplification to Enable AI Datacenter Networks

Coherent Expands Pluggable Optical Line Systems Portfolio with Full C-Band Amplification to Enable AI Datacenter Networks

Coherent Corp. announced an expansion of its Pluggable Optical Line System (POLS) portfolio to include a full C-band, high-power variable-gain amplifier optical line system in a compact QSFP form factor. This system supports the latest 800G ZR/ZR+ digital coherent optics, enabling up to 25.6Tbps AI datacenter traffic across link distances from 2km …

Hudson Technologies Signs Joint Development Agreement with Icorium; Expands Commitment to Commercialize and Scale Patented Extractive Distillation Technology

Hudson Technologies Signs Joint Development Agreement with Icorium; Expands Commitment to Commercialize and Scale Patented Extractive Distillation Technology

Hudson Technologies has signed a joint development agreement with Icorium Company to commercialize Icorium's patented extractive distillation technology. This collaboration aims to enhance Hudson's refrigerant reclamation systems by enabling faster and more complete separation of complex refrigerant mixtures, improving efficiency and expanding thei…

Globus Maritime Announces Results of Annual Meeting of Shareholders

Globus Maritime Announces Results of Annual Meeting of Shareholders

Globus Maritime Limited, a dry bulk shipping company listed on NASDAQ, held its annual meeting of shareholders in Glyfada, Greece. The shareholders approved the election of two directors to serve until 2029 and appointed Ernst & Young (Hellas) as independent auditors for the fiscal year ending 2026. The company operates a fleet of ten dry bulk vess…

argenx announces results of Extraordinary General Meeting of Shareholders and appointment of Thomas M. Brakel and Khurem Farooq as Non-Executive Directors

argenx announces results of Extraordinary General Meeting of Shareholders and appointment of Thomas M. Brakel and Khurem Farooq as Non-Executive Directors

argenx SE announced the results of its Extraordinary General Meeting of Shareholders, including the appointments of Thomas M. Brakel and Khurem Farooq as non-executive directors. The company emphasizes its ongoing focus on scientific innovation, shareholder value, and long-term growth aligned with its Vision 2030 strategy.

U.S. to Grant Visas for Limited Iranian Delegation to U.N. General Assembly

U.S. to Grant Visas for Limited Iranian Delegation to U.N. General Assembly

The U.S. State Department announced that a restricted Iranian delegation will be allowed to attend next week’s United Nations General Assembly in New York, with visas issued to key officials but subject to travel and purchase limitations. The move comes amid ongoing hostilities between Washington and Tehran and intermittent negotiations aimed at en…

Capital Southwest Announces SBA Approval to Increase Leverage Commitment Available to Capital Southwest SBIC II, LP

Capital Southwest Announces SBA Approval to Increase Leverage Commitment Available to Capital Southwest SBIC II, LP

Capital Southwest Corporation announced that the U.S. Small Business Administration has approved an increase in the leverage commitment available to its wholly owned subsidiary, Capital Southwest SBIC II, LP, raising it from $175 million to $250 million. This enhancement will support the company's strategy of deploying capital to lower middle marke…

Leonardo DRS to Provide Electric Propulsion System for the Republic of Korea Navy Next-Generation KDDX Destroyer Program

Leonardo DRS to Provide Electric Propulsion System for the Republic of Korea Navy Next-Generation KDDX Destroyer Program

Leonardo DRS has won a contract from Doosan Enerbility to supply an integrated electric power and propulsion system for the Republic of Korea Navy's KDDX destroyer program, marking South Korea's first fully indigenously designed and built destroyer class. The system will feature Leonardo DRS's advanced permanent magnet motors and variable frequency…

Xenon Announces Azetukalner NDA Submission to FDA for Focal Seizures and Provides Update on Psychiatry Clinical Program

Xenon Announces Azetukalner NDA Submission to FDA for Focal Seizures and Provides Update on Psychiatry Clinical Program

Xenon Pharmaceuticals announced the submission of a New Drug Application (NDA) for azetukalner to treat focal seizures to the FDA, supported by positive Phase 2b and Phase 3 clinical trial data demonstrating efficacy and safety. The company continues enrollment in ongoing Phase 3 epilepsy studies but has voluntarily paused enrollment in psychiatry …

Ultragenyx Announces Approval of FAYUVI™ Gene Therapy, the First-Ever FDA-Approved Treatment for Sanfilippo Syndrome Type A (MPS IIIA)

Ultragenyx Announces Approval of FAYUVI™ Gene Therapy, the First-Ever FDA-Approved Treatment for Sanfilippo Syndrome Type A (MPS IIIA)

Ultragenyx Pharmaceutical announces FDA full approval of FAYUVI™ (rebisufligene etisparvovec-hopf), the first-ever gene therapy treatment for pediatric patients with Sanfilippo syndrome Type A (MPS IIIA), a devastating and fatal neurodegenerative disease. The approval follows positive pivotal clinical data demonstrating FAYUVI's ability to slow dis…